Enokizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IL9 |
Clinical data | |
ATC code | none |
Identifiers | |
ChemSpider | none |
UNII |
I4BE5F78HR ![]() |
Chemical and physical data | |
Formula | C6492H10000N1704O2038S44 |
Molar mass | 148.4 kg/mol |
![]() ![]() |
Enokizumab is a humanized monoclonal antibody designed for the treatment of asthma.[1]
Enokizumab was developed by MedImmune.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab" (PDF). American Medical Association.
IL-1 |
| ||||||
---|---|---|---|---|---|---|---|
IL-2 |
| ||||||
IL-3 |
| ||||||
IL-4 |
| ||||||
IL-5 |
| ||||||
IL-6 |
| ||||||
IL-7 |
| ||||||
IL-8 |
| ||||||
IL-9 |
| ||||||
IL-10 |
| ||||||
IL-11 |
| ||||||
IL-12 |
| ||||||
IL-13 |
| ||||||
IL-15 |
| ||||||
IL-17 |
| ||||||
IL-18 |
| ||||||
IL-20 |
| ||||||
IL-21 |
| ||||||
IL-22 |
| ||||||
IL-23 |
| ||||||
IL-27 |
| ||||||
IL-28 |
| ||||||
IL-31 |
| ||||||
IL1RL1 |
| ||||||
IL1RL2 |
| ||||||
Others |
| ||||||
|
This article is issued from Wikipedia - version of the 9/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.